Corrigendum: Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors

Subjects

Subjects :

endometrial cancer
molecular classification
immune checkpoint inhibitors
dostarlimab
pembrolizumab plus lenvatinib
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282

Details

Language :

English

ISSN :

2234943X

Volume :

13

Database :

Directory of Open Access Journals

Journal :

Frontiers in Oncology

Publication Type :

Academic Journal

Accession number :

edsdoj.f619c78545464a823c5d3ef4cc8cc3

Document Type :

article

Full Text :

https://doi.org/10.3389/fonc.2023.1357793